Sanofi on Reinforcing Research and Development To Help Vulnerable Communities in the Wake of the COVID-19 Pandemic

Originally published on LinkedIn and at sanofi.com. Sanofi U.S. ranked No. 27 on The Fair360, formerly DiversityInc Top 50 Companies for Diversity list in 2021.

 

The COVID-19 pandemic has highlighted inequalities around the world, which have driven us to deepen our commitment to society.

As part of our social impact strategy, we are committed to reinforcing our R&D innovation to help vulnerable communities. We continue developing innovative vaccines and medicines to eradicate polio, helping people suffering from sleeping sickness in sub-Saharan Africa, and reduce childhood cancer deaths.

  • Polio: One of our key priorities is to help eradicate polio. Sanofi has partnered with the Global Polio Eradication Initiative (GPEI) for almost 30 years and has provided UNICEF with polio vaccines at preferential prices through GAVI, the Vaccine Alliance, which aims to vaccinate populations in 73 of the poorest countries, to eradicate the disease.
  • Sleeping sickness is a neglected tropical disease (NTD) that affects the poorest populations living in sub-Saharan Africa. For years, we have partnered with DNDi to develop and provide innovative drugs to ensure patients living in the most remote areas have access to treatment. We are also collaborating with the World Health Organization (WHO) to donate drugs and provide financial support to programs in the field.
  • Childhood cancer: A child living in a low- and middle-income country is four times more likely to die from childhood cancer compared to a child raised in a high-income country. To combat this inequality, we will develop innovative medicines with the ambition to ultimately eliminate cancer deaths in children.

To read more about Sanofi’s social impact strategy, click here.